Overview
- The companies signed a definitive all-stock merger agreement Monday that will combine the businesses under the Slate Medicines name and pursue a Nasdaq listing under the ticker SLTE.
- A $245 million private placement led by Frazier Life Sciences will back the transaction and the firms say the financing and existing cash are expected to fund operations into 2029 and advance SLTE-1009 into Phase I and a Phase II dose-ranging study.
- Under the deal Fulcrum is expected to contribute about $20.3 million in net cash, pay a pre-closing cash dividend to its shareholders estimated at roughly $270 million, and leave pre-merger Fulcrum holders with about 5% of the combined company while Slate investors and new backers hold roughly 95%.
- Fulcrum discontinued development of its PRC2-targeting sickle cell candidate after an FDA trial hold and safety signals about secondary blood cancers, and the merged company will prioritize Slate’s SLTE-1009 anti-PACAP/VIP antibody and SLTE-2100 bispecific with SLTE-2100 planned to enter trials in the second half of 2027.
- Fulcrum cut about 85% of its workforce during restructuring and the deal, which names Gregory Oakes CEO, is targeted to close in the fourth quarter of 2026 subject to regulatory and shareholder approvals with near-term milestones including trial starts and the Nasdaq listing.